At Novartis, curiosity and purpose drive us forward in our mission to ensure no heart is lost too soon. In this video, colleagues share how Novartis’ values inspire them to stay curious, committed, and focused on reimagining medicine to create a meaningful impact for patients worldwide. 🎥 Watch Part 2 now—and see how our people are shaping a brighter, healthier future. Dr. Miles Braithwaite, Ph.D. Nicolas Alberto Costa Franck Perraudin, PhD Madlaina Costa-Scharplatz #Cardiology #HeartHealth #NoHeartLostTooSoon #WorldHeartDay #WorldHeartDay2025
Info
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
Externer Link zu Novartis
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel, Baselstadt
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand und Gene and cell therapy
Orte
Beschäftigte von Novartis
-
David Yee
Head Portfolio Systems & Capabilities, Enterprise Portfolio Insights, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
-
Jennifer Ma
Updates
-
We’re proud to support ABC Global Alliance #VisionOfADecade initiative, amplifying voices of global leaders and shaping the future of advanced breast cancer care. #BreastCancerAwarenessMonth #BCAM #BreastCancer
This #BreastCancerAwarenessMonth, we’re looking ahead to the next decade of change. Ten years ago, we set out with 10 clear to transform care for people living with advanced breast cancer (ABC). We’ve seen meaningful progress, but there’s still critical work to do. We invited global leaders (patients, clinicians, researchers and advocates) to share their vision for the future of ABC care. ❓What progress must we demand? ❓What does a better future look like for those affected by ABC? Introducing #VisionOfADecade: a powerful series spotlighting these voices of change. Throughout October, hear their stories and insights, each one helping shape the ABC Global Charter for 2025–2035. Learn more about our work and the official launch of the Global Decade Report and Global Charter at #ABC8 on November 6th #ABClisbon Fatima Cardoso OncoDaily OncoAlert #ABCGlobalAlliance #KnowledgeinMotion #ABC8 #BCAM #MetastaticBreastCancer
-
1 in 8 women will face breast cancer in their lifetime – it’s a reality that touches lives, families, and communities.¹ At Novartis, we bring over 35 years of groundbreaking innovation to redefine what is possible for people with breast cancer. We are committed to addressing unmet needs and driving progress in breast cancer care – from early diagnosis, working toward a cure, to extending life in advanced settings. Through bold science, AI-powered personalized care, and partnerships, we are improving lives today and shaping a future where people living with the disease experience improved outcomes. Learn more: https://lnkd.in/gyn8t7HH #BreastCancerAwarenessMonth #BCAM #BreastCancer
-
Malaria medicine for infants, launched. In Ghana, we’ve just introduced the first malaria medicine specifically designed for babies under 5kg. And thanks to a collaborative procedure with the Swiss therapeutics agency Swissmedic, more African countries may follow soon. It’s a proud moment for all of us at Novartis, and one of many milestones in our long journey towards malaria elimination. Explore our immersive web experience now to learn how we’ve been delivering breakthroughs since the 1990s, how we went first for the smallest babies together with our partners, and how we’re going further with new innovations in malaria. Learn more here: https://bit.ly/436fEA9 Medicines for Malaria Venture I European & Developing Countries Clinical Trials Partnership (EDCTP)
-
At Novartis we are not just responding to today’s treatment challenges — we are reimagining medicine to improve and extend people‘s lives, transforming the promise of next-generation cancer care into a reality today. As a pioneer in radioligand therapy (RLT) with an expanding global infrastructure, Novartis is committed to shaping a better future for patients with prostate cancer and beyond. See what the future of RLT looks like at the Novartis booth. https://lnkd.in/gwWDrJew #EANM2025
-
At Novartis, our people are at the heart of our mission to ensure no heart is lost too soon. Hear from colleagues what inspires them in their work, how curiosity drives innovation, and how Novartis' values empower them to improve and extend lives every day. 🎥 Watch Part 1 now and stay tuned for Part 2! #Cardiology #HeartHealth #NoHeartLostTooSoon #WorldHeartDay #WorldHeartDay2025
-
Novartis helped establish radioligand therapy (RLT) as an innovative treatment modality — and we’re not stopping there. Through ongoing commitment in research, access, and supply, Novartis is dedicated to building a new standard of care in prostate cancer, and beyond. Visit us at #EANM2025 to see our continued commitment in action. https://lnkd.in/g8Cz6ek3
-
“I feel my heart bumping.” That’s how one colleague reacted when reading our people’s reflections on mental health and wellbeing. From personal promises to team commitments, our colleagues are proving that wellbeing starts with me, you, us. Words become action, and care for each other begins with care for ourselves. #MentalHealthMonth #CollectiveCommitment #ThriveTogether
-
The symptoms of chronic spontaneous urticaria (CSU) are often minimized, yet can have a significant impact on patients living with the disease. This World Urticaria Day, Tonya Winders, president & CEO of Global Allergy & Airways Patient Platform, shares her thoughts on the challenges that CSU patients face and the need for more effective treatments. #ReimaginingMedicine
-
The FDA approval of a new oral, targeted therapy for chronic spontaneous urticaria (CSU) changes the treatment landscape for millions of people living with this often-overlooked disease. This milestone represents our continued commitment to expanding our immunology portfolio and addressing the unmet needs of patients with immune-related conditions.
Today’s FDA approval of a new oral, targeted therapy for chronic spontaneous urticaria (CSU) brings new hope to the millions of CSU patients in the US struggling with symptoms. We are thankful to the researchers, community members, and advocates who partnered with us in bringing this new treatment option to patients. 🔗 Read more: http://bit.ly/483NlWx #ReimagineMedicine #NovartisUS
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Novartis
Insgesamt 2 Finanzierungsrunden
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.487.694.394,00 $